Infusions of stem cells derived from umbilical cords proved safe for people with neuromyelitis optica spectrum disorder (NMOSD) and look to be a promising new therapy for the autoimmune disease, according to data from an early clinical trial conducted in China. In the trial, the two-year treatment, which consisted…
News
For adults with neuromyelitis optica spectrum disorder (NMOSD), rituximab and Uplizna (inebilizumab) work equally well to prevent disease relapses, but Uplizna appears to be safer because it causes fewer infusion-related side effects. Those are the main findings of a real-world study analyzing data from more than 250 NMOSD…
Treatment with Enspryng (satralizumab) for more than two years was shown to prevent relapses in most people with neuromyelitis optica spectrum disorder (NMOSD) in Japan. That’s according to a new study that tracked outcomes from Japanese NMOSD patients given the approved injection therapy in real-world practice. “Overall, most…
Depletion of sex hormone production by surgical removal of the ovaries significantly lessened activation of microglia — the brain’s immune cells —as well as neuroinflammation and nerve cell damage in female mice with induced neuromyelitis optica spectrum disorder (NMOSD)-like disease, a study shows. Similar effects were found in castrated…
In 2018, when Nell Choi was 9 years old, she began experiencing symptoms that led to hospitalization and a diagnosis of neuromyelitis optica spectrum disorder (NMOSD), type positive. A month later, when Nell came home, she was weak, in a wheelchair, and had lost 20 pounds. To…
Specific nerve damage and shrinkage in key brain regions are associated with a faster time to relapse and worsening disability among adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against the AQP4 protein, according to a study in Italy. Researchers used advanced MRI techniques to…
March is NMOSD Awareness Month, and advocates around the world are working to educate others and raise the profile of neuromyelitis optica spectrum disorder (NMOSD), also known as neuromyelitis optica or, simply, NMO. A major international initiative this year is to name March 27 as World NMOSD Awareness Day.
Therapies specifically approved by the U.S. Food and Drug Administration (FDA) for neuromyelitis optica spectrum disorder (NMOSD) are superior to rituximab and other off-label medications at preventing relapses and serious side effects, according to a real-world study in the U.S. The study also showed that among FDA-approved therapies, the…
Nearly a third of people with neuromyelitis optica spectrum disorder (NMOSD) may have cognitive impairment, especially in the areas of attention/processing speed and executive function, according to a study in Brazil. Processing speed refers to a person’s ability to receive, interpret, and respond to information, while executive function refers…
Add-on hyperbaric oxygen therapy (HBOT), which involves breathing pure oxygen at high pressure, may help reduce inflammation in people with neuromyelitis optica spectrum disorder (NMOSD), especially those with more overactive immune systems, a small study suggests. “HBOT may help rebalance the immune system in NMOSD,” researchers wrote, noting that…
Recent Posts
- Use of umbilical cord cells shown to safely cut relapses in NMOSD in trial
- The 3-inch high heels that were an act of rebellion against NMOSD
- 2 NMOSD drugs show equal power at preventing disease relapses
- Confessions of the kind of NMOSD patient doctors warn their interns about
- Real-world data show Enspryng reduces NMOSD relapses over 2.5 years